MX361375B - Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano. - Google Patents

Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano.

Info

Publication number
MX361375B
MX361375B MX2015011385A MX2015011385A MX361375B MX 361375 B MX361375 B MX 361375B MX 2015011385 A MX2015011385 A MX 2015011385A MX 2015011385 A MX2015011385 A MX 2015011385A MX 361375 B MX361375 B MX 361375B
Authority
MX
Mexico
Prior art keywords
tryptophan
inhibitors
treating
metabolization
tricyclic compounds
Prior art date
Application number
MX2015011385A
Other languages
English (en)
Other versions
MX2015011385A (es
Inventor
Mautino Mario
Kumar Sanjeev
Waldo Jesse
Jaipuri Firoz
Original Assignee
Newlink Genetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50686105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX361375(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newlink Genetics Corp filed Critical Newlink Genetics Corp
Publication of MX2015011385A publication Critical patent/MX2015011385A/es
Publication of MX361375B publication Critical patent/MX361375B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan actualmente los inhibidores de IDO y TDO y las composiciones farmacéuticas de los mismos, útiles para modular una actividad de la indolamina-2,3-dioxigenasa y la triptófano-2,3-dioxigenasa; el tratamiento de la inmunosupresión; el tratamiento de una condición médica que beneficia de la inhibición de la degradación de triptófano; el mejoramiento de la efectividad de un tratamiento anticanceroso que comprende administrar un agente anti-canceroso; el tratamiento de la inmunosupresión específica del tumor asociada con el cáncer; y el tratamiento de la inmunosupresión asociada con una enfermedad infecciosa.
MX2015011385A 2013-03-14 2014-03-10 Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano. MX361375B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784089P 2013-03-14 2013-03-14
PCT/US2014/022680 WO2014159248A1 (en) 2013-03-14 2014-03-10 Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization

Publications (2)

Publication Number Publication Date
MX2015011385A MX2015011385A (es) 2016-02-03
MX361375B true MX361375B (es) 2018-12-05

Family

ID=50686105

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011385A MX361375B (es) 2013-03-14 2014-03-10 Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano.

Country Status (22)

Country Link
US (2) US9617272B2 (es)
EP (2) EP3366678A1 (es)
JP (2) JP6093903B2 (es)
KR (1) KR20150126623A (es)
CN (1) CN105189466A (es)
AU (2) AU2014241079C1 (es)
BR (1) BR112015022588A2 (es)
CA (1) CA2902174A1 (es)
CL (2) CL2015002649A1 (es)
CR (1) CR20150485A (es)
HK (1) HK1213259A1 (es)
IL (1) IL241027A0 (es)
MA (1) MA38493B1 (es)
MX (1) MX361375B (es)
PE (1) PE20151593A1 (es)
PH (1) PH12015501866A1 (es)
RU (1) RU2667509C2 (es)
SA (1) SA515361127B1 (es)
SG (2) SG11201507255QA (es)
UA (1) UA118103C2 (es)
WO (1) WO2014159248A1 (es)
ZA (1) ZA201607948B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2694640T3 (es) 2011-04-15 2018-03-17
EA029052B1 (ru) 2013-03-14 2018-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
JP6467404B2 (ja) 2013-03-14 2019-02-13 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７モジュレーター
WO2014152589A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
CN103570727B (zh) 2013-11-12 2015-08-19 复旦大学 一种n-苄基色胺酮衍生物及其制备方法和应用
WO2016037026A1 (en) * 2014-09-05 2016-03-10 Merck Patent Gmbh Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
AP2017009733A0 (en) 2014-09-12 2017-02-28 Boehringer Ingelheim Int Spirocyclic inhibitors of cathepsin c
US10150766B2 (en) 2014-09-12 2018-12-11 Janssen Pharmaceutica Nv P2X7 modulators
GB201417369D0 (en) * 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
CA2965741C (en) * 2014-11-03 2022-05-17 Iomet Pharma Ltd Pharmaceutical compound
WO2016100851A1 (en) 2014-12-18 2016-06-23 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
CN105884828A (zh) 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
EP3280715B1 (en) 2015-04-10 2020-11-25 Beigene, Ltd. NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
US10358451B2 (en) 2015-04-12 2019-07-23 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as IDO and TDO inhibitors
CA2985642A1 (en) * 2015-05-15 2016-11-24 Gilead Sciences, Inc. Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
CN105037371A (zh) * 2015-06-30 2015-11-11 西华大学 一种氘代的吲哚胺-2,3-双加氧酶抑制剂
CA2992016C (en) 2015-07-24 2019-10-22 Newlink Genetics Corporation Salts and prodrugs of 1-methyl-d-tryptophan
JP7227005B2 (ja) 2015-12-24 2023-02-21 ジェネンテック， インコーポレイテッド Ｔｄｏ２阻害剤
CN107056785B (zh) * 2016-01-02 2021-06-22 杭州英创医药科技有限公司 作为ido和tdo抑制剂的杂环化合物
WO2017134555A1 (en) 2016-02-02 2017-08-10 Emcure Pharmaceuticals Limited Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
CN112898309A (zh) * 2016-02-19 2021-06-04 正大天晴药业集团股份有限公司 作为免疫调节剂的三并环化合物
CN108884104B (zh) * 2016-02-19 2021-01-15 正大天晴药业集团股份有限公司 作为免疫调节剂的三并环化合物
WO2017149469A1 (en) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Heterocyclic compounds useful as ido and/or tdo modulators
KR102456521B1 (ko) * 2016-04-29 2022-10-20 아이오메트 파마 엘티디 인돌아민 2,3-디옥시게나제 및/또는 트립토판-2,3-디옥시게나제의 억제제로서의 신규 치환된 이미다조피리딘 화합물
WO2017198159A1 (zh) * 2016-05-16 2017-11-23 鲁南制药集团股份有限公司 含桥环的咪唑衍生物
CN107383012B (zh) * 2016-05-16 2021-09-28 鲁南制药集团股份有限公司 含二环的咪唑醇衍生物
CN107663159A (zh) * 2016-07-29 2018-02-06 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
US11607426B2 (en) 2016-09-19 2023-03-21 University Of South Florida Method of targeting oncolytic viruses to tumors
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
EP3515914A4 (en) * 2016-09-24 2020-04-15 BeiGene, Ltd. NEW IMIDAZO [1,5-A] PYRIDINES SUBSTITUTED IN POSITION 5 OR 8 AS INDOLEAMINE AND / OR TRYPTOPHANE 2,3-DIOXYGENASES
AU2017343780B2 (en) 2016-10-13 2023-08-31 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
TW201815793A (zh) * 2016-10-21 2018-05-01 江蘇恆瑞醫藥股份有限公司 一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法
WO2018113624A1 (zh) * 2016-12-20 2018-06-28 深圳微芯生物科技有限责任公司 具有吲哚胺2,3-双加氧酶抑制活性的稠合咪唑化合物
PT3559009T (pt) 2016-12-22 2021-05-04 Calithera Biosciences Inc Composições e métodos para inibir a atividade da arginase
JP2020506895A (ja) 2017-01-17 2020-03-05 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物
US11603373B2 (en) 2017-06-28 2023-03-14 Genentech, Inc. TDO2 and IDO1 inhibitors
WO2019006047A1 (en) 2017-06-28 2019-01-03 Genentech, Inc. INHIBITORS OF TDO2 AND IDO1
CN109384791B (zh) * 2017-08-09 2020-09-11 江苏恒瑞医药股份有限公司 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法
CA3075870A1 (en) * 2017-09-15 2019-03-21 Taiho Pharmaceutical Co., Ltd. Prophylactic and/or therapeutic agent for diseases involving ido expression
US20200239452A1 (en) * 2017-10-19 2020-07-30 General Incorporated Association Pharma Valley Project Supporting Organization IDO/TDO Inhibitor
WO2019101188A1 (en) 2017-11-25 2019-05-31 Beigene, Ltd. Novel benzoimidazoles as selective inhibitors of indoleamine 2, 3-dioxygenases
KR20200106513A (ko) 2018-01-05 2020-09-14 다이서나 파마수이티컬, 인크. 면역요법을 강화시키기 위하여 베타-카테닌 및 ido 발현의 감소
EP3768666A1 (en) 2018-03-20 2021-01-27 Plexxikon Inc. Compounds and methods for ido and tdo modulation, and indications therefor
US11046649B2 (en) 2018-07-17 2021-06-29 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
TW202035409A (zh) 2018-09-28 2020-10-01 比利時商健生藥品公司 單醯基甘油脂肪酶調節劑
EA202190886A1 (ru) 2018-09-28 2021-09-07 Янссен Фармацевтика Нв Модуляторы моноацилглицерин-липазы
CN114555596A (zh) 2019-09-30 2022-05-27 詹森药业有限公司 放射性标记的mgl pet配体
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
WO2022184930A2 (en) 2021-03-05 2022-09-09 Universität Basel Compositions for the treatment of ebv associated diseases or conditions
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH516573A (de) * 1967-08-15 1971-12-15 Sandoz Ag Verfahren zur Herstellung von 5-Hydroxy-5-phenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindolen
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
WO1999029310A2 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
AU2002307243B2 (en) 2002-04-12 2008-01-03 Medical College Of Georgia Research Institute, Inc. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
BRPI0311179A2 (pt) * 2002-05-15 2016-06-21 Janssen Pharmaceutica Nv 3-aminopirazóis tricíclicos n-substituídos como inibidores de receptor de pdfg
EP2260846B1 (en) 2003-03-27 2018-11-28 Lankenau Institute for Medical Research Novel methods for the treatment of cancer
DE102007020493A1 (de) 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Amid-Derivate
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
WO2009132238A2 (en) 2008-04-24 2009-10-29 Newlink Genetics Ido inhibitors
WO2010056567A1 (en) * 2008-11-13 2010-05-20 Merck Sharp & Dohme Corp. Imidazoisoindole neuropeptide s receptor antagonists
WO2011056652A1 (en) * 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
JP2012037986A (ja) 2010-08-04 2012-02-23 Canon Inc 画像形成装置及びその制御方法と画像形成システム
NO2694640T3 (es) 2011-04-15 2018-03-17

Also Published As

Publication number Publication date
AU2014241079B2 (en) 2016-12-15
EP3366678A1 (en) 2018-08-29
KR20150126623A (ko) 2015-11-12
IL241027A0 (en) 2015-11-30
ZA201607948B (en) 2018-05-30
EP2976332A1 (en) 2016-01-27
PH12015501866A1 (en) 2015-12-07
EP2976332B1 (en) 2018-01-31
AU2014241079A1 (en) 2015-09-03
CL2015002649A1 (es) 2016-07-29
RU2015143990A (ru) 2017-04-19
CR20150485A (es) 2015-11-26
CL2016001940A1 (es) 2017-03-10
JP2017052786A (ja) 2017-03-16
SG11201507255QA (en) 2015-10-29
US9617272B2 (en) 2017-04-11
BR112015022588A2 (pt) 2017-07-18
AU2014241079B9 (en) 2017-04-06
US20170260188A1 (en) 2017-09-14
SA515361127B1 (ar) 2017-10-19
AU2017201693A1 (en) 2017-03-30
JP2016519056A (ja) 2016-06-30
MX2015011385A (es) 2016-02-03
SG10201707545XA (en) 2017-10-30
US9981973B2 (en) 2018-05-29
UA118103C2 (uk) 2018-11-26
AU2014241079C1 (en) 2017-07-06
WO2014159248A1 (en) 2014-10-02
JP6093903B2 (ja) 2017-03-08
HK1213259A1 (zh) 2016-06-30
MA38493A1 (fr) 2017-02-28
PE20151593A1 (es) 2015-11-05
US20160060266A1 (en) 2016-03-03
MA38493B1 (fr) 2017-10-31
RU2667509C2 (ru) 2018-09-21
JP6352368B2 (ja) 2018-07-04
CA2902174A1 (en) 2014-10-02
CN105189466A (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
PH12015501866A1 (en) Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
MX2013012021A (es) Derivados de imidazol fusionados utiles como inhibidores de indoleamina 2-3 dioxigenasa (ido).
GEP20217247B (en) Indole derivatives for use in medicine
PH12017502079A1 (en) Treatment of beta-thalassemia using actrii ligand traps
PH12015502028A1 (en) Ido inhibitors
PH12016502132A1 (en) Aryl-or heteroaryl-substituted benzene compounds
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
NZ708382A (en) Cycloalkyl bis-thiadiazole inhibitors of glutaminase and their use as therapeutic agents
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
EA201591599A1 (ru) Ингибиторы ido
MX2015004771A (es) Metodos para tratar cancer.
MX344530B (es) Compuestos de benceno substituido.
UA111386C2 (uk) Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2015014181A (es) 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
MX2017012102A (es) Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti.
PH12017502046A1 (en) Salts and prodrugs of 1-methyl-d-tryptophan
CL2016001361A1 (es) Regimen de dosificación para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa

Legal Events

Date Code Title Description
FG Grant or registration